文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

一种基于纳米颗粒的 COVID-19 疫苗候选物能诱导广泛的中和抗体，并能预防 SARS-CoV-2 感染。

A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection.

机构信息

Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.

Neurosciences, Laval University, 2705 boulevard Laurier, Québec City, QC G1V 4G2, Canada.

出版信息

Nanomedicine. 2022 Aug;44:102584. doi: 10.1016/j.nano.2022.102584. Epub 2022 Jul 16.

DOI:10.1016/j.nano.2022.102584
PMID:35850421
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9287509/
Abstract

A vaccine candidate to SARS-CoV-2 was constructed by coupling the viral receptor binding domain (RBD) to the surface of the papaya mosaic virus (PapMV) nanoparticle (nano) to generate the RBD-PapMV vaccine. Immunization of mice with the coupled RBD-PapMV vaccine enhanced the antibody titers and the T-cell mediated immune response directed to the RBD antigen as compared to immunization with the non-coupled vaccine formulation (RBD + PapMV nano). Anti-RBD antibodies, generated in vaccinated animals, neutralized SARS-CoV-2 infection in vitro against the ancestral, Delta and the Omicron variants. At last, immunization of mice susceptible to the infection by SARS-CoV-2 (K18-hACE2 transgenic mice) with the RBD-PapMV vaccine induced protection to the ancestral SARS-CoV-2 infectious challenge. The induction of the broad neutralization against SARS-CoV-2 variants induced by the RBD-PapMV vaccine demonstrate the potential of the PapMV vaccine platform in the development of efficient vaccines against viral respiratory infections.

摘要

一种针对 SARS-CoV-2 的疫苗候选物是通过将病毒受体结合域（RBD）与木瓜花叶病毒（PapMV）纳米颗粒（nano）的表面偶联来构建的，从而生成 RBD-PapMV 疫苗。与非偶联疫苗制剂（RBD+PapMV nano）相比，用偶联的 RBD-PapMV 疫苗免疫小鼠增强了针对 RBD 抗原的抗体滴度和 T 细胞介导的免疫反应。在接种疫苗的动物中产生的抗 RBD 抗体，在体外中和了针对原始、Delta 和奥密克戎变体的 SARS-CoV-2 感染。最后，用 RBD-PapMV 疫苗免疫易感染 SARS-CoV-2 的小鼠（K18-hACE2 转基因小鼠），诱导对原始 SARS-CoV-2 感染性挑战的保护。RBD-PapMV 疫苗诱导的针对 SARS-CoV-2 变体的广泛中和反应表明，PapMV 疫苗平台在开发针对病毒性呼吸道感染的有效疫苗方面具有潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cc/9287509/64d4ec3b8075/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cc/9287509/a804eb8660c9/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cc/9287509/53ea5c12b720/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cc/9287509/39d7b2c6af7d/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cc/9287509/644e8789839b/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cc/9287509/55f23fe02fb6/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cc/9287509/ed98be454404/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cc/9287509/64d4ec3b8075/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cc/9287509/a804eb8660c9/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cc/9287509/53ea5c12b720/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cc/9287509/39d7b2c6af7d/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cc/9287509/644e8789839b/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cc/9287509/55f23fe02fb6/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cc/9287509/ed98be454404/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20cc/9287509/64d4ec3b8075/gr6_lrg.jpg

相似文献

[1]
A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection.

Nanomedicine. 2022-8

[2]
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.

Elife. 2022-8-25

[3]
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.

J Virol. 2022-9-14

[4]
A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling.

J Nanobiotechnology. 2017-7-18

[5]
Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.

Vaccine. 2023-7-31

[6]
RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.

mSphere. 2022-8-31

[7]
A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2.

Emerg Microbes Infect. 2022-12

[8]
A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice.

Front Immunol. 2022

[9]
A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern.

Emerg Microbes Infect. 2023-12

[10]
Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.

Front Immunol. 2022

引用本文的文献

[1]
Strategies for developing self-assembled nanoparticle vaccines against SARS-CoV-2 infection.

Front Immunol. 2024

[2]
Plant Viruses as Adjuvants for Next-Generation Vaccines and Immunotherapy.

Vaccines (Basel). 2023-8-16

[3]
SARS-CoV-2 S Glycoprotein Stabilization Strategies.

Viruses. 2023-2-17

[4]
A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19).

Antibodies (Basel). 2023-1-11

本文引用的文献

[1]
COVID-19 vaccine development: milestones, lessons and prospects.

Signal Transduct Target Ther. 2022-5-3

[2]
Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.

PLoS Med. 2022-2

[3]
TLR7 Signaling Shapes and Maintains Antibody Diversity Upon Virus-Like Particle Immunization.

Front Immunol. 2021

[4]
Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron.

Cell. 2022-3-3

[5]
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

Cell. 2022-2-3

[6]
Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants.

Vaccines (Basel). 2022-1-3

[7]
Heterologous prime-boost strategies for COVID-19 vaccines.

J Travel Med. 2022-5-31

[8]
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.

Lancet. 2021-12-18

[9]
Thrombotic events and COVID-19 vaccines.

Int J Tuberc Lung Dis. 2021-9-1

[10]
How protein-based COVID vaccines could change the pandemic.

Nature. 2021-11

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索